Protective Effects of Chaihu Shugan San (柴胡疏肝散) on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance

2016 ◽  
Vol 24 (2) ◽  
pp. 125-132 ◽  
Author(s):  
Wei-ning Jiang ◽  
Dan Li ◽  
Tao Jiang ◽  
Jiao Guo ◽  
Yan-fen Chen ◽  
...  
2018 ◽  
Vol 2 (12) ◽  
pp. 1467-1478 ◽  
Author(s):  
Christopher J. Danford ◽  
Margery A. Connelly ◽  
Irina Shalaurova ◽  
Misung Kim ◽  
Mark A. Herman ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Xiaoyun Wei ◽  
Chunyan Wang ◽  
Shijun Hao ◽  
Haiyan Song ◽  
Lili Yang

Aim. To assess the efficacy of berberine in the treatment of nonalcoholic fatty liver disease through meta-analysis.Method. We searched Embase, Pubmed, Cochrane Library, and so forth, until March 2016 for randomized controlled trials using berberine to treat NAFLD.Result. Six randomized controlled trials involving 501 patients were included in this study. The results showed that the efficacy of reducing TC, LDL, ALT, 2hPG, and HbA1c in NAFLD patients of the berberine group were significantly higher than that of control group. The subgroup analyses on TG, AST, and FBG indicated that treatment combined with berberine decreased TG level in NAFLD patients significantly. Compared with other drugs, berberine alone decreased TG level in NAFLD patients significantly. We also conducted a descriptive analysis on insulin resistance and radiography results that berberine can improve NAFLD patients’ insulin resistance and fatty liver.Conclusion. According to analysis result, berberine has positive efficacy on blood lipids, blood glucose, liver function, insulin resistance, and fatty liver condition of NAFLD patients. However, due to the limitation of number and quality of trials included, more clinical randomized controlled trials with high quality are needed for further verification of the efficacy of berberine on NAFLD patients.


2010 ◽  
Vol 18 (30) ◽  
pp. 3175
Author(s):  
Bing-Fang Wang ◽  
Pei-Ying Tian ◽  
Kun Feng ◽  
Fu-Rong Wu ◽  
Yong-Gao Lu ◽  
...  

Hepatology ◽  
2008 ◽  
Vol 48 (3) ◽  
pp. 792-798 ◽  
Author(s):  
Anna Ludovica Fracanzani ◽  
Luca Valenti ◽  
Elisabetta Bugianesi ◽  
Marco Andreoletti ◽  
Agostino Colli ◽  
...  

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Hannah E. Da Silva ◽  
Anastasia Teterina ◽  
Elena M. Comelli ◽  
Amel Taibi ◽  
Bianca M. Arendt ◽  
...  

2019 ◽  
Vol 49 (5) ◽  
pp. 903-910 ◽  
Author(s):  
Mehrnaz Nikkhah-Bodaghi ◽  
Matin Ghanavati ◽  
Azita Hekmatdoost

PurposePolyphenols are plant-derived bioactive compounds with some known hepato-protective effects. The purpose of this study is to evaluate the association between polyphenol consumption and risk of nonalcoholic fatty liver disease (NAFLD) and its related conditions such as impaired lipid profile and elevated hepatic enzymes.Design/methodology/approachA total of 196 NAFLD patients and 803 controls were enrolled in this case-control study. Biochemical and anthropometric measurements as well as polyphenol consumption during the previous year were assessed.FindingsIn unadjusted model, participants who consumed the third and fourth quartiles of polyphenols intake were less likely to have NAFLD in comparison to those who consumed the first quartile [odds ratio, OR: 0.48; 95 per cent confidence interval, CI: (0.30-0.77) and OR: 0.62; 95 per cent CI: (0.40-0.96), respectively]. In separate analysis of genders, this effect was seen only in male participants [OR: 0.29; 95 per cent CI: (0.14-0.58) and OR: 0.21; 95 per cent CI (0.10-0.42), respectively], and the association remained significant after adjustment for energy, body mass index, age and smoking.Originality/valueHigher total polyphenol intake is associated with a decreased risk of NAFLD. Prospective studies are needed to confirm these results.


Sign in / Sign up

Export Citation Format

Share Document